Zuranolone for the Treatment of Postpartum Depression

Overview of attention for article published in American Journal of Psychiatry, July 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#19 of 7,782)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 7 posts from 6 blogs.

A look back on 2023's breakthrough research and the most important stories related to pregnancy, childbirth, and postpartum…

The U.S. Food and Drug Administration (FDA) on Friday approved Zurzuvae (zuranolone), the first oral medication for the…

In a landmark achievement for the field of women’s physical and mental health and wellness, the Food and Drug Administration…

MONDAY, July 31, 2023 (HealthDay News) — For women with severe postpartum depression (PPD), zuranolone yields significant…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity, including 3 additional blog posts.